Lineage Cell Therapeutics (LCTX) Prepaid Assets (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Prepaid Assets of $2.0 million for Q1 2026, up 5.95% year-over-year from $1.9 million in Q1 2025, and down 20.44% quarter-over-quarter from $2.5 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Prepaid Assets (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Prepaid Assets history runs 17 years deep, the most recent figure standing at $2.0 million for Q1 2026.
- In Q1 2026, Prepaid Assets rose 5.95% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $2.0 million (up 5.95% YoY), while the FY2025 annual figure was $2.5 million, down 2.7% from the prior year.
- Prepaid Assets for Q1 2026 stood at $2.0 million, down from $2.5 million in the prior quarter.
- The five-year high for Prepaid Assets was $2.6 million in Q1 2023, with the low at $1.3 million in Q3 2024.
- The 5-year median for Prepaid Assets is $1.8 million (2022), against an average of $1.9 million.
- The sharpest annual moves came in 2022 and 2023: Prepaid Assets slumped 48.54% in 2022, then soared 86.69% in 2023.
- Lineage Cell Therapeutics' Prepaid Assets stood at $1.8 million in 2022, then advanced by 20.57% to $2.2 million in 2023, then gained by 15.88% to $2.6 million in 2024, then retreated by 2.7% to $2.5 million in 2025, then slipped by 20.44% to $2.0 million in 2026.
- Business Quant data shows LCTX's Prepaid Assets at $2.0 million in Q1 2026, $2.5 million in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.35 Mn |
| Mar 31, 2026 | 1.98 Mn |
| Dec 31, 2025 | 2.49 Mn |
| Sep 30, 2025 | 1.65 Mn |
| Jun 30, 2025 | 1.30 Mn |
| Mar 31, 2025 | 1.87 Mn |
| Dec 31, 2024 | 2.55 Mn |
| Sep 30, 2024 | 1.29 Mn |
| Jun 30, 2024 | 1.66 Mn |
| Mar 31, 2024 | 2.02 Mn |
| Dec 31, 2023 | 2.20 Mn |
| Sep 30, 2023 | 1.72 Mn |
| Jun 30, 2023 | 2.12 Mn |
| Mar 31, 2023 | 2.64 Mn |
| Dec 31, 2022 | 1.83 Mn |
| Sep 30, 2022 | 1.72 Mn |
| Jun 30, 2022 | 1.29 Mn |
| Mar 31, 2022 | 1.41 Mn |
| Dec 31, 2021 | 2.35 Mn |
| Sep 30, 2021 | 3.16 Mn |